Biofrontera AG provided sales guidance for the fourth quarter and full year ended December 31, 2018. The preliminary unaudited revenue of the company for the period January 1 to December 31, 2018 was between EUR 21.0 and EUR 21.2 million. This represents a revenue growth of approximately 76% compared to the previous year period, with pure product sales increasing by around 98%.

Revenue in the fourth quarter will amount to about EUR 6.6 million, compared to EUR 4.7 million in the previous year.

The company has revised its forecast for the 2018 consolidated net loss from EUR 15.0 to EUR 16.0 million to EUR 8.0 to EUR 10.0 million.